- Gun Violence Reduction Law Further Extends Moratorium on Trump-Era Rebate Rule June 27, 2022
- 10th Annual Legal, Regulatory & Compliance Forum on Dietary Supplements is Just Days Away June 24, 2022
- Corporate Liability from Employee Diversion: Costly on Many Fronts June 22, 2022
- ‘Til I Hear It From Congress: FDASLA to Direct Publication of Final OTC Hearing Aid Rules June 22, 2022
- In Bid to Curtail 180-day Exclusivity, FDA Alters Longstanding Practice and Newly Declares that Converted OTC Products Are Not “Listed Drugs” June 21, 2022
- Big Molecule Watch Blog
- Bloomberg BNA Health Care Blog
- Drug and Device Law Blog
- Eye on FDA
- FDA Matters
- Harvard Law Bill of Health
- IN VIVO Blog
- Internet Drug News.com
- Lachman Consultants Blog
- Medical Devices Today
- Orange Book Blog
- The Orange Book Insights Blog
- Pharma IQ
- Pharmalot
- SCOTUS Blog
- The Volokh Conspiracy
- WLF Legal Pulse
- Advertising and Promotion (Federal Trade Commission)
- Advertising and Promotion (OPDP)
- Animal Drugs and Feeds
- Biosimilars
- Cannabis
- cGMP Compliance
- Consumer Product Safety Commission
- Controlled Substances
- Cosmetics
- COVID19
- Current Affairs
- Dietary Supplements
- Drug Development
- Drug Enforcement Administration
- Enforcement
- FDA News
- Foods
- Foods and Dietary Supplements
- Fraud and Abuse
- Government Pricing
- Hatch-Waxman
- Health Care
- Health Privacy
- Import/Export
- In Vitro Diagnostic Devices
- Jobs
- Medical Devices
- Miscellaneous
- Orphan Drugs
- OTC Drugs and Cosmetics
- Prescription Drugs and Biologics
- Product Jurisdiction and Combination Products
- Reimbursement
- Tissue Products
- Tobacco
- Uncategorized
HP&M’s Adrienne Lenz to Present on Deciphering New and Proposed Regulatory Guidances for Medical Devices and Diagnostics
December 21, 2021Hyman, Phelps & McNamara, P.C. is pleased to announce that Adrienne Lenz will be speaking on Deciphering New and Proposed Regulatory Guidances For Medical Devices and Diagnostics at the Q1 Productions 4th Annual Life Science Regulatory Intelligence Virtual Event being held January 24-25, 2022. The foundation of the regulatory intelligence and strategy is to remain abreast of current regulatory and legislative guidelines. The magnitude of guidance documents affecting a product throughout its lifecycle makes this a continual challenge for regulatory teams. This session will highlight current guidance documents that are of key importance to device and diagnostic manufacturers and regulatory intelligence executives. This virtual event brings together global intelligence, strategy, policy and legal experts to share best practices on challenges faced by regulatory teams.
FDA Law Blog readers are offered a discount of 15% off the registration price. The case-sensitive discount code is Q1HPM15. You can access conference information and register for the event here.
Search FDA Law Blog
Subscribe
Latest Tweets
Tweets by @fdalawblogAwards & Honors
- The Best
Lawyers in America
US News & World Report - Ranked in Chambers USA 2018
- Gun Violence Reduction Law Further Extends Moratorium on Trump-Era Rebate Rule June 27, 2022
- 10th Annual Legal, Regulatory & Compliance Forum on Dietary Supplements is Just Days Away June 24, 2022
- Corporate Liability from Employee Diversion: Costly on Many Fronts June 22, 2022
- ‘Til I Hear It From Congress: FDASLA to Direct Publication of Final OTC Hearing Aid Rules June 22, 2022
- In Bid to Curtail 180-day Exclusivity, FDA Alters Longstanding Practice and Newly Declares that Converted OTC Products Are Not “Listed Drugs” June 21, 2022
- Big Molecule Watch Blog
- Bloomberg BNA Health Care Blog
- Drug and Device Law Blog
- Eye on FDA
- FDA Matters
- Harvard Law Bill of Health
- IN VIVO Blog
- Internet Drug News.com
- Lachman Consultants Blog
- Medical Devices Today
- Orange Book Blog
- The Orange Book Insights Blog
- Pharma IQ
- Pharmalot
- SCOTUS Blog
- The Volokh Conspiracy
- WLF Legal Pulse
- Advertising and Promotion (Federal Trade Commission)
- Advertising and Promotion (OPDP)
- Animal Drugs and Feeds
- Biosimilars
- Cannabis
- cGMP Compliance
- Consumer Product Safety Commission
- Controlled Substances
- Cosmetics
- COVID19
- Current Affairs
- Dietary Supplements
- Drug Development
- Drug Enforcement Administration
- Enforcement
- FDA News
- Foods
- Foods and Dietary Supplements
- Fraud and Abuse
- Government Pricing
- Hatch-Waxman
- Health Care
- Health Privacy
- Import/Export
- In Vitro Diagnostic Devices
- Jobs
- Medical Devices
- Miscellaneous
- Orphan Drugs
- OTC Drugs and Cosmetics
- Prescription Drugs and Biologics
- Product Jurisdiction and Combination Products
- Reimbursement
- Tissue Products
- Tobacco
- Uncategorized